US Patent

US11357782 — Treprostinil administration by inhalation

Method of Use · Assigned to United Therapeutics Corp · Expires 2027-05-14 · 1y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of administering the drug treprostinil using a metered dose inhaler.

USPTO Abstract

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Drugs covered by this patent

Remodulin (TREPROSTINIL) · United Therap

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1849`	—	Remodulin
`U-1849`	—	Remodulin
`U-1849`	—	Remodulin
`U-1849`	—	Remodulin
`U-1849`	—	Remodulin

Patent Metadata

Patent number: US11357782
Jurisdiction: US
Classification: Method of Use
Expires: 2027-05-14
Drug substance claim: No
Drug product claim: No
Assignee: United Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.